scholarly journals Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Kheng-Wei Yeoh ◽  
N. George Mikhaeel
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Survival Rates ◽  
Hodgkin's Lymphoma ◽  
Ongoing Research ◽  
Modern Treatment ◽  
Modality Approach ◽  
Therapeutic Radiation ◽  
Modern Radiotherapy

Hodgkin's Lymphoma was incurable until the advent of effective therapeutic radiation around the first half of the 20th century. As survival rates improved, the long-term toxicities from radiotherapy began to emerge. This together with the availability of effective chemotherapy has encouraged a combined modality approach for early-staged disease and the omission of radiotherapy in advanced-staged disease. The differing toxicities of radiotherapy and chemotherapy has promoted ongoing research to identify the utility of each of these modalities in the modern management of Hodgkin's Lymphoma. This article will provide a critical review of the developments and indications for modern radiotherapy, in context with advances in chemotherapy, for the treatment of Hodgkin's Lymphoma.

scholarly journals The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Evgeny Klyuchnikov ◽  
Ulrike Bacher ◽  
Nicolaus Kröger ◽  
Ilya Kazantsev ◽  
Tatjana Zabelina ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Special Focus ◽  
Term Survival

Despite the favorable prognosis of most patients with Hodgkin's Lymphoma (HL), 15–20% of patients remain refractory to chemoradiotherapy, and 20–40% experience relapses following autologous stem cell transplantation (SCT) being used as salvage approach in this situation. Long-term survival of only 20% was reported for patients who failed this option. As some authors suggested the presence of a graft versus HL effect, allogeneic SCT was introduced as a further option. Myeloablative strategies were reported to be able to achieve cure in some younger patients, but high nonrelapse mortality remains a problem. Reduced intensity conditioning, in turn, was found to be associated with high posttransplant relapse rates. As there is currently no standard in the management of HL patients who failed autologous SCT, we here review the literature on allogeneic stem cell transplantation in HL patients with a special focus on the outcomes and risk factors being reported in the largest studies.

The autologous hemopoietic stem cell transplantation in adult patients with lymphoma: Turkish Bone Marrow Transplantation Registry Results

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 17517-17517
Author(s):  
T. Turkish
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Survival Rates ◽  
Hodgkin's Lymphoma ◽  
Hemopoietic Stem Cell ◽  
Term Survival ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
First Remission ◽  
Hemopoietic Stem Cell Transplantation

17517 Background: Turkish bone marrow transplantation registry (TBMTR) was established in 1995. Since 1992, data of adult lymphoma patients from fifteen transplant centers were collected and analyzed by TBMTR. Methods: A total of 437 adult lymphoma patients (185 Hodgkin’s and 252 non-Hodgkin’s lymphoma) undergoing autologous hemopoietic stem cell transplantation (HSCT) were registered by TBMTR from 1992 to 2002. Results: Peripheral blood was used in 94% of the transplantations as a source of stem cells. Non-TBI conditioning regimens were administered in 88% of the cases. The 100-day transplant related mortality was 11% in relapsed and in primary refractory Hodgkin’s lymphoma patients; while transplant-related mortality (TRM) was found to be 9% and 30% in non-Hodgkin’s lymphoma patients in first remission and in primary refractory cases, respectively. Infection was the most common cause of TRM. Overall (long-term) survival rates were 50% and 49% in relapsed cases and primary refractory cases with Hodgkin’s lymphoma, respectively; while in non-Hodgkin’s lymphoma patients the survival rates were 65% in cases in first remission, 50% in sensitive relapse, 0% in resistant relapse and 24% in primary refractory cases. Conclusions: In conclusion, TBMTR results are comparable to EBMT and IBMTR results. Therefore, autologous HSCT may provide long-term survival in patients with Hodgkin’s lymphoma as well as in patients with non-Hodgkin lymphoma in first remission and in sensitive relapse. Contributing authors and centers: F. Arpaci1, S. Ataergin1, G. Gurman2, S. Cagirgan3, M. Arat2, A. Ozet1, M. Ayli4, M. Ozcan2, A. Unal5, T. Soysal6, Y. Koc7, A. Buyukcelik8, A. Ozturk9, E. Ovali10, H. Goker11, B. Sahin12, S. Kalayoglu Besisik13, M. Bayik14, Z. Bolaman15, S. Bavbek16, M. Turan1 1GATA; 2Ankara University Hematology; 3Ege University; 4Numune Hospital, Ankara; 5Erciyes University; 6Cerrahpasa University; 7Hacettepe University Institute of Oncology; 8Ankara University Medical Oncology; 9GATA Haydarpasa; 10Karadeniz University; 11Hacettepe University; 12Cukurova University; 13Istanbul University Hematology; 14Marmara University; 15A.Menderes University; 16Istanbul University Institute of Oncology. No significant financial relationships to disclose.

Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma

2007 ◽  
Vol 48 (4) ◽  
pp. 723-730 ◽  
Author(s):  
Filippo Russo ◽  
Secondo Lastoria ◽  
Gino Svanera ◽  
Gaetana Capobianco ◽  
Anna de Chiara ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ca 125 ◽  
Newly Diagnosed ◽  
Follow Up Study ◽  
Long Term Follow Up

Sexual Functioning in Long-Term Survivors of Hodgkin's Lymphoma

2008 ◽  
Author(s):  
Veronica Sanchez Varela ◽  
Sharon Bober ◽  
Andrea Ng ◽  
Peter Mauch ◽  
Christopher Recklitis
Keyword(s):  
Sexual Functioning ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Long Term Survivors

The role of interleukins and the widely studied TNF-α in non-Hodgkin’s lymphoma

2021 ◽  
Vol 38 (5) ◽  
Author(s):  
Kyle P. D’mello ◽  
Lei Zhao ◽  
Erin C. Kaser ◽  
Ziwen Zhu ◽  
Huaping Xiao ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Tnf Α
Sign in / Sign up

Export Citation Format

Share Document